Group 4A: HER2+ Breast Cancer; Antibody-drug Conjugates; Brain Metastasis; Clinical Trials; Novel Targets & Therapies



Thursday, June 15
10:00 am – 11:30 am Eastern Time (US/New York)


Click Here to Join Zoom Event

Poster #1041: 

Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases

Poster #1044:

Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study

View Poster PDFs

Mentor: TBD

TBD

Twitter:

Scientist: Guilherme Nader Marta, M.D., Ph.D. Candidate

Guilherme Nader Marta received his medical degree from the University of Sao Paulo (Brazil) and completed his oncology residency in the same institution. Since 2021, he has joined Jules Bordet Institute in Belgium as a clinical research fellow, where his time is dedicated to breast cancer research.

He is currently a PhD candidate at the Universite Libre de Bruxelles (ULB) with a research line in biomarkers and breast cancer special histological types, particularly lobular breast cancer.

The results of his research have been presented at international conferences, published in peer-reviewed journals and, in recognition for the high quality of his work, he received a Conquer Cancer Merit Award in 2022 and a Young Investigator Award in 2023.

Twitter: @Nader_Guilherme